A selective inhibitor of clinically important mutants of EGFR tyrosine kinase

摘要

We have a selective inhibitory effect on the protein kinase which is resistant to the existing EGFR inhibition, especially the type I receptor tyrosine kinase (RTK) family or ErbB family, with lung cancer, colorectal cancer, pancreatic cancer, head and neck cancer, breast cancer, ovarian cancer, uterine cancer Provide a new compound useful for the treatment of cancer such as liver cancer and gastric cancer.A compound having the following structural formula is shown.No selection